DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
NCT ID: NCT00897936
Last Updated: 2020-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
418 participants
OBSERVATIONAL
2006-03-23
2009-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking at tissue samples from patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia
NCT01434329
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT00899366
Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia
NCT00898261
Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01057095
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
NCT01139931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine gene expression, genome integrity, cytosine methylation, and chromatin structure in patients with normal cytogenetics leukemia (NCL) acute myeloid leukemia.
* Determine whether NCL can be deconstructed into specific disease entities by analysis of the integrated genomic and epigenomic datasets using supervised and unsupervised methods in these patients.
* Identify the gene pathways that define NCL subtypes and molecular targets for validation in preclinical and clinical trials for these patients.
* Determine whether integrated analysis provides markers of prognostic and therapeutic response that accurately predicts clinical outcome and can be used to select patients for risk-stratified therapeutic trials.
OUTLINE: This is a pilot, multicenter study.
Samples are analyzed to assess array comparative genomic hybridization using polymerase chain reaction (PCR) and fluorescent in situ hybridization; chromatin immunoprecipitations (chip) using PCR; Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) using DNA methylation analysis; and gene expression profiling.
PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
comparative genomic hybridization
fluorescence in situ hybridization
microarray analysis
polymerase chain reaction
diagnostic laboratory biomarker analysis
immunologic technique
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia
* Enrolled on clinical trial ECOG-E1900
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
ECOG-ACRIN Cancer Research Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ari M. Melnick, MD
Role: STUDY_CHAIR
Albert Einstein College of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECOG-E1900T2
Identifier Type: -
Identifier Source: secondary_id
CDR0000476571
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.